Lecanemab

Lecanemab is a medication designed to treat Alzheimer’s disease by targeting and removing beta-amyloid plaques in the brain. These plaques are thought to contribute to the progression of Alzheimer’s by disrupting communication between brain cells. Lecanemab is a type of monoclonal antibody, meaning it is engineered to specifically recognize and bind to these abnormal proteins. Clinical trials have shown that it may slow cognitive decline in some patients, offering hope for better management of the disease. It represents an important step in Alzheimer’s treatment, aiming to improve quality of life for those affected.